frizzled related proteinGenealiases: FRE · FRITZ · FRP-3 · FRZB-1 · FRZB-PEN · FRZB1
Q-omics provides the consensus-scored FRZB profile across patient tissues and cancer cell-line models. FRZB expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, FRZB is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, FRZB protein abundance shows 25,229 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight HNSC, KICH, and PDAC as cancer lineages where FRZB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FRZB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FRZB survival associations across molecular data types. FRZB RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FRZB RNA expression–survival associations across cancer types. High FRZB expression shows unfavorable associations in KIRP and UVM, but favorable associations in HNSC, LUAD, KIRC and MESO. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for FRZB RNA expression.
This table summarizes FRZB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for FRZB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FRZB shows lower tumor expression in KICH, HNSC, COAD and KIRP and higher tumor expression in LIHC and KIRC. The KICH box plot shows higher FRZB RNA expression in normal versus tumor tissue (log2 FC = −3.210, t-test p < 0.001).
This table shows molecular features associated with FRZB in patient tissues and cancer cell lines. In patient samples, FRZB shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, FRZB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
